We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Roche has partnered with UK-based Adaptimmune Therapeutics to develop “off-the-shelf” T-cell therapies for up to five cancer targets in a deal valued at $150 million upfront but potentially worth up to $3 billion to the UK company. Read More
The FDA approved Aduhelm in early June, despite the drug showing only moderate benefit in one phase 3 trial and no benefit in another late-stage study. Read More
The co-founders of Taiwan-based JHL Biotech have pleaded guilty in a federal court of stealing trade secrets from Roche’s subsidiary Genentech. Read More
The companies will use Lycia’s lysosomal targeting chimera platform to develop new medicines for as many as five protein targets across different Lilly research areas. Read More
A federal appeals court has reversed a $1.2 billion ruling which found Gilead Sciences’ cancer immunotherapy Yescarta (axicabtagene ciloleucel) infringed on a Bristol Myers Squibb (BMS) patent for CAR-T technology. Read More
In addition to potential Alzheimer’s and Parkinson’s therapies, Shape said it may use its adeno-associated virus platform to help identify other gene therapy targets, including for rare diseases. Read More
South Korean conglomerate Samsung, which already manufactures Moderna’s COVID-19 vaccine, plans to increase its involvement in the biopharmaceuticals space. Read More
TTI-622 and TTI-621 are the only CD47-targeted molecules to show meaningful monotherapy activity and complete responses across multiple hematological malignancies, the companies said. Read More